Indian study on treating diabetics with heart ailments gets

A path-breaking Indian clinical trial is making the world medical fraternity to take a re-look at the treatment of diabetics with heart ailments.
The trial, carried out by the Academics and Research department of Fortis Escorts Heart Institute led by Professor Dr Upendra Kaul on 1,830 patients in 46 Indian hospitals, puts at rest a decade-old medical controversy on the comparative superiority of stents in diabetics.
The randomised study demonstrates the superiority of Everolimus eluting stents over Paclitaxel eluting stents which will help improve outcomes in treatment of diabetic patients with coronary blocks.
As per the findings, the use of Everolimus eluting stents may be equally or more useful in treating coronary blockages in diabetic patients than bypass surgery.

The study was presented at the 'Trans catheter Cardiovascular Therapeutics' (TCT) conference in San Fransisco, considered the largest gathering of eminent cardiologists. It has also made it to the prestigious New England Journal of Medicine.
"The study conclusively showed that 'Everolimus eluting stents' are superior than 'Paclitaxel eluting stents', putting to rest a decade-old controversy in the medical world. It demonstrated that they are not equal," Prof Kaul told PTI.
With over 40 million diabetics, India is known as diabetes capital of the world and the findings of the research will come in handy in treating those who have developed heart ailments.

Drug eluting stents are medicine-coated which helps to open blocked arteries, Priyadarshini Arambram, who was part of the study said, explaining how they are different from normal stents.